|
“The search for bioactive
metabolites from marine microbes has only just begun”—David Newman, D. Phil,
and Russell Hill, PhD, New Drugs from Marine Microbes: The Tide is Turning
(2006)
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to determine the current status of the
global marine-derived pharmaceutical market, including its growth potential
during the period of 2011 to 2016. Our key objective is to present a
comprehensive analysis of marine life and technology as they relate to
pharmaceutical applications and to forecast this market’s future direction.
REASONS FOR DOING THIS STUDY
Our understanding of marine life only began during the last half of the 20th
century. The first marine discovery that led to a pharmaceutical drug began in
the 1950s when chemists Bergmann and Feeney isolated nucleosidic compounds from
the Caribbean sponge Cryptotethya crypta. Marine drugs on the market
today can be traced to this discovery (e.g., anticancer drug cytarabine).
While marine life is used for many applications, including food and industrial
processing, its use in the pharmaceutical industry has just begun. Marine life
offers a complex and diverse genetic resource unavailable on land, which has
led to the exploration of the oceans to find new tests and cures for illnesses.
Entire classes of antibiotics desperately needed for a world surviving on
relatively few antibiotics, which people are becoming resistant to, could be
found in just a few marine samples.
This report describes the potential of marine research and its growth
prospects. It is estimated that marine-derived drugs will essentially double in
number from 2011 to 2016. Because marine-derived drugs already account for a
few powerful drugs, this area of the drug industry has already generated
billions of dollars to date.
SCOPE OF REPORT
The scope of this study encompasses research organizations, the U.S. government chiefly in the form of the National Cancer
Institute (NCI), and companies that develop or help in the development process
of pharmaceuticals derived from marine life. Included are extensive
descriptions, perspectives, and predictive information, including forecasts of
growth over the next 5 years. Technological issues, including the latest
trends, are discussed.
INTENDED AUDIENCE
In this report, marine-derived pharmaceuticals are described in terms of their
history in medicine, technology types and categories, research organizations,
major companies, impact on the pharmaceutical market, applications, current
market values, growth potential, and significant trends. This study will be of
interest to non-profits and the government sector as well as the biotechnology
and pharmaceutical industries and related life science, analytics, drug
discovery, and diagnostic test manufacturing companies as well as all those
interested in or actively working in drug and imaging agent research and
investors in all of the above.
METHODOLOGY
BCC presents an analysis of the types of technologies, applications, and
therapeutic areas representing the financial value of marine-derived
pharmaceuticals. Estimated values are based on actual aggregate sales for the
years discussed. Information, in general, is compiled through a combination of
primary and secondary research, including annual reports and interviews with
company and government officials as well as experts in academia.
INFORMATION SOURCES
BCC’s analysis includes the review of more than 50 companies and information
from financial and trade publications as well as the U.S. Food and Drug
Administration (FDA). Included were pharmaceutical and biotechnology companies
as well as support companies to them.
To order this report:
: Global Markets for Marine-Derived Pharmaceuticals
More Market Research Report
Check our Industry Analysis and
Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
| 
